↓ Skip to main content

Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma

Overview of attention for article published in Journal of Gastrointestinal Surgery, October 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
30 Mendeley
Title
Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma
Published in
Journal of Gastrointestinal Surgery, October 2016
DOI 10.1007/s11605-016-3285-x
Pubmed ID
Authors

Yan Zhao, Rafael Duran, Julius Chapiro, Jae Ho Sohn, Sonia Sahu, Florian Fleckenstein, Susanne Smolka, Timothy M Pawlik, Rüdiger Schernthaner, Li Zhao, Howard Lee, Shuixiang He, MingDe Lin, Jean-François Geschwind

Abstract

It remains controversial whether transarterial chemoembolization (TACE) should be performed in patients with advanced-stage hepatocellular carcinoma (HCC). The present large retrospective cohort study aimed to define the survival outcome following TACE of advanced HCC and to identify the prognostic factors. Five hundred eight patients with Barcelona Clinic Liver Cancer (BCLC) C-stage HCC, Child-Pugh A/B who were treated with TACE between November 1998 and December 2013 were identified. There was no significant difference in overall survival (OS) between patients with Eastern Cooperative Oncology Group (ECOG) 0 and those with ECOG ≥1 (10.5 months vs. 11.9 months, P = 0.87). The median OS of patients without portal vein tumor thrombosis (PVTT) was longer than that of patients with PVTT (16.9 vs. 6.1 months, P < 0.001). Child-Pugh B class, PVTT, extrahepatic metastasis, tumor size ≥5 cm, number of tumors ≥3, and alpha-fetoprotein ≥400 ng/dL were significantly associated with decreased survival and were used for determining the risk scores. All patients were divided into two groups (low-risk and high-risk groups) according to the cutoff value of 6.5 for risk scores. The patients with a value <6.5 (low-risk group) had significantly longer survival than those with >6.5 (high-risk group) (24.1 vs. 7.5 months, respectively; P < 0.001). TACE is an effective therapy for select patients with advanced stage HCC and may provide equal or improved survival as compared with reported outcomes with sorafenib. The results highlight the need for a differentiated approach to therapeutic recommendations for patients with BCLC C.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 17%
Student > Bachelor 3 10%
Researcher 3 10%
Student > Postgraduate 2 7%
Student > Ph. D. Student 2 7%
Other 4 13%
Unknown 11 37%
Readers by discipline Count As %
Medicine and Dentistry 12 40%
Nursing and Health Professions 3 10%
Psychology 2 7%
Computer Science 1 3%
Materials Science 1 3%
Other 0 0%
Unknown 11 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2016.
All research outputs
#22,759,802
of 25,374,647 outputs
Outputs from Journal of Gastrointestinal Surgery
#2,082
of 2,485 outputs
Outputs of similar age
#286,854
of 327,136 outputs
Outputs of similar age from Journal of Gastrointestinal Surgery
#42
of 61 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,485 research outputs from this source. They receive a mean Attention Score of 4.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,136 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.